Skip to main content
Erschienen in: Basic Research in Cardiology 2/2010

01.03.2010 | Original Contribution

Depressed expression of MuRF1 and MAFbx in areas remote of recent myocardial infarction: a mechanism contributing to myocardial remodeling?

verfasst von: Viviane M. Conraads , Christiaan J. Vrints, Inez E. Rodrigus, Vicky Y. Hoymans, Emeline M. Van Craenenbroeck, Johan Bosmans, Marc J. Claeys, Paul Van Herck, Axel Linke, Gerhard Schuler, Volker Adams

Erschienen in: Basic Research in Cardiology | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Ventricular remodeling following myocardial infarction (MI) includes myocardial hypertrophy, a process requiring increased protein synthesis and sarcomere assembly. The anti-hypertrophic effect of MuRF1/MafBx, both muscle-specific E3-ubiquitin ligases, has been demonstrated in animal experiments and in cultured cardiomyocytes. We assessed MuRF1/MAFbx expression in myocardium remote of recently (<2 weeks) infarcted regions (MI), compared with patients undergoing coronary artery bypass surgery, with normal systolic function and without previous infarction (control or Con). Left ventricular myocardial biopsies were obtained from the contralateral normal zone in MI (n = 14) patients and from the Con (n = 12) group. MuRF-1/MAFbx expression was assessed using RT-PCR and Western blot (WB). In addition, the myocardial expression of TNF-α was measured (RT-PCR) and troponin I, β-myosin and phosphorylated Akt/Akt (pAkt/Akt) were quantified (WB). MuRF1 and MAFbx expression (mRNA and protein level) were significantly reduced in biopsies from MI patients. TNF-α was significantly higher in MI and exhibited a negative correlation with MuRF1 and MAFbx. The expression of troponin I and cardiomyocyte size were increased in MI in comparison to Con, whereas β-myosin expression was not altered. When compared with Con, pAkt/Akt was elevated. The results of the present study suggest that the atrogenes MuRF1/MAFbx are involved in regulating the hypertrophic response, characteristic of the early post-infarction remodeling phase. Reduced expression of MuRF1 and MAFbx in the myocardium might permit hypertrophy, which is supported by the elevation of troponin I. A regulatory role of TNF-α needs to be confirmed in further experiments.
Literatur
1.
Zurück zum Zitat Abbate A, Biondi-Zoccai GG, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM, Baldi A (2003) Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 41:753–760CrossRefPubMed Abbate A, Biondi-Zoccai GG, Bussani R, Dobrina A, Camilot D, Feroce F, Rossiello R, Baldi F, Silvestri F, Biasucci LM, Baldi A (2003) Increased myocardial apoptosis in patients with unfavorable left ventricular remodeling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 41:753–760CrossRefPubMed
2.
Zurück zum Zitat Adams V, Linke A, Gielen S, Erbs S, Hambrecht R, Schuler G (2008) Modulation of Murf-1 and MAFbx expression in the myocardium by physical exercise training. Eur J Cardiovasc Prev Rehabil 15:293–299CrossRefPubMed Adams V, Linke A, Gielen S, Erbs S, Hambrecht R, Schuler G (2008) Modulation of Murf-1 and MAFbx expression in the myocardium by physical exercise training. Eur J Cardiovasc Prev Rehabil 15:293–299CrossRefPubMed
3.
Zurück zum Zitat Adams V, Linke A, Wisloff U, Doring C, Erbs S, Krankel N, Witt CC, Labeit S, Muller-Werdan U, Schuler G, Hambrecht R (2007) Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res 73:120–129CrossRefPubMed Adams V, Linke A, Wisloff U, Doring C, Erbs S, Krankel N, Witt CC, Labeit S, Muller-Werdan U, Schuler G, Hambrecht R (2007) Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res 73:120–129CrossRefPubMed
4.
Zurück zum Zitat Anversa P, Olivetti G, Capasso JM (1991) Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 68:7D–16DCrossRefPubMed Anversa P, Olivetti G, Capasso JM (1991) Cellular basis of ventricular remodeling after myocardial infarction. Am J Cardiol 68:7D–16DCrossRefPubMed
5.
Zurück zum Zitat Anversa P, Olivetti G, Li P, Herman MV, Capasso JM (1993) Myocardial infarction, cardiac anatomy and ventricular loading. Cardioscience 4:55–62PubMed Anversa P, Olivetti G, Li P, Herman MV, Capasso JM (1993) Myocardial infarction, cardiac anatomy and ventricular loading. Cardioscience 4:55–62PubMed
6.
Zurück zum Zitat Arya R, Kedar V, Hwang JR, McDonough H, Li HH, Taylor J, Patterson C (2004) Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J Cell Biol 167:1147–1159CrossRefPubMed Arya R, Kedar V, Hwang JR, McDonough H, Li HH, Taylor J, Patterson C (2004) Muscle ring finger protein-1 inhibits PKC{epsilon} activation and prevents cardiomyocyte hypertrophy. J Cell Biol 167:1147–1159CrossRefPubMed
7.
Zurück zum Zitat Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, Bang ML, Trombitas K, Granzier H, Gregorio CC, Sorimachi H, Labeit S (2001) Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306:717–726CrossRefPubMed Centner T, Yano J, Kimura E, McElhinny AS, Pelin K, Witt CC, Bang ML, Trombitas K, Granzier H, Gregorio CC, Sorimachi H, Labeit S (2001) Identification of muscle specific ring finger proteins as potential regulators of the titin kinase domain. J Mol Biol 306:717–726CrossRefPubMed
8.
Zurück zum Zitat Condorelli G, Morisco C, Latronico MV, Claudio PP, Dent P, Tsichlis P, Frati G, Drusco A, Croce CM, Napoli C (2002) TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J 16:1732–1737CrossRefPubMed Condorelli G, Morisco C, Latronico MV, Claudio PP, Dent P, Tsichlis P, Frati G, Drusco A, Croce CM, Napoli C (2002) TNF-alpha signal transduction in rat neonatal cardiac myocytes: definition of pathways generating from the TNF-alpha receptor. FASEB J 16:1732–1737CrossRefPubMed
9.
Zurück zum Zitat Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821–1828CrossRefPubMed Depre C, Wang Q, Yan L, Hedhli N, Peter P, Chen L, Hong C, Hittinger L, Ghaleh B, Sadoshima J, Vatner DE, Vatner SF, Madura K (2006) Activation of the cardiac proteasome during pressure overload promotes ventricular hypertrophy. Circulation 114:1821–1828CrossRefPubMed
10.
Zurück zum Zitat Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher A (1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells. Circ Res 83:334–341PubMed Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher A (1998) Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells. Circ Res 83:334–341PubMed
11.
Zurück zum Zitat Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J (2008) Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 295:H1206–H1215CrossRefPubMed Fang CX, Dong F, Thomas DP, Ma H, He L, Ren J (2008) Hypertrophic cardiomyopathy in high-fat diet-induced obesity: role of suppression of forkhead transcription factor and atrophy gene transcription. Am J Physiol Heart Circ Physiol 295:H1206–H1215CrossRefPubMed
12.
Zurück zum Zitat Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN (2007) Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 117:2486–2495CrossRefPubMed Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN (2007) Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 117:2486–2495CrossRefPubMed
13.
Zurück zum Zitat Fielitz J, van Rooij E, Spencer JA, Shelton JM, Latif S, van der Nagel R, Bezprozvannaya S, de Windt L, Richardson JA, Bassel-Duby R, Olson EN (2007) Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc Natl Acad Sci USA 104:4377–4382CrossRefPubMed Fielitz J, van Rooij E, Spencer JA, Shelton JM, Latif S, van der Nagel R, Bezprozvannaya S, de Windt L, Richardson JA, Bassel-Duby R, Olson EN (2007) Loss of muscle-specific RING-finger 3 predisposes the heart to cardiac rupture after myocardial infarction. Proc Natl Acad Sci USA 104:4377–4382CrossRefPubMed
14.
Zurück zum Zitat Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37:1974–1984PubMed Glass DJ (2005) Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 37:1974–1984PubMed
15.
Zurück zum Zitat Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Kitamura T, Ogawa W, Yokoyama M (2001) TNF-alpha induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes. Am J Physiol Heart Circ Physiol 280:H1861–H1868PubMed Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Kitamura T, Ogawa W, Yokoyama M (2001) TNF-alpha induces protein synthesis through PI3-kinase-Akt/PKB pathway in cardiac myocytes. Am J Physiol Heart Circ Physiol 280:H1861–H1868PubMed
16.
Zurück zum Zitat Houser SR, Margulies KB (2003) Is depressed myocyte contractility centrally involved in heart failure? Circ Res 92:350–358CrossRefPubMed Houser SR, Margulies KB (2003) Is depressed myocyte contractility centrally involved in heart failure? Circ Res 92:350–358CrossRefPubMed
17.
Zurück zum Zitat Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen W, Shou Z, Liu P (1999) Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 99:1492–1498PubMed Irwin MW, Mak S, Mann DL, Qu R, Penninger JM, Yan A, Dawood F, Wen W, Shou Z, Liu P (1999) Tissue expression and immunolocalization of tumor necrosis factor-α in postinfarction dysfunctional myocardium. Circulation 99:1492–1498PubMed
18.
Zurück zum Zitat Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C (2004) Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 101:18135–18140CrossRefPubMed Kedar V, McDonough H, Arya R, Li HH, Rockman HA, Patterson C (2004) Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I. Proc Natl Acad Sci USA 101:18135–18140CrossRefPubMed
19.
Zurück zum Zitat Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627–635PubMed Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res 81:627–635PubMed
20.
Zurück zum Zitat Lauten A, Majos E, Mühlich A, Wahlers T, Weider S, Fischer JH, Figulla HR, Bloch W (2009) Ischemia-reperfusion injury activates early extracellular matrix processing and expression of endostatin in the heart with differential effects of temperature. Basic Res Cardiol 104:559–569CrossRefPubMed Lauten A, Majos E, Mühlich A, Wahlers T, Weider S, Fischer JH, Figulla HR, Bloch W (2009) Ischemia-reperfusion injury activates early extracellular matrix processing and expression of endostatin in the heart with differential effects of temperature. Basic Res Cardiol 104:559–569CrossRefPubMed
21.
Zurück zum Zitat Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114:1058–1071PubMed Li HH, Kedar V, Zhang C, McDonough H, Arya R, Wang DZ, Patterson C (2004) Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex. J Clin Invest 114:1058–1071PubMed
22.
Zurück zum Zitat Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C (2007) Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of forkhead proteins. J Clin Invest 117:3211–3223CrossRefPubMed Li HH, Willis MS, Lockyer P, Miller N, McDonough H, Glass DJ, Patterson C (2007) Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of forkhead proteins. J Clin Invest 117:3211–3223CrossRefPubMed
23.
Zurück zum Zitat Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988–998CrossRefPubMed Mann DL (2002) Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res 91:988–998CrossRefPubMed
24.
Zurück zum Zitat Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837–2849CrossRefPubMed Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837–2849CrossRefPubMed
25.
Zurück zum Zitat Patterson C, Ike C, PWt Willis, Stouffer GA, Willis MS (2007) The bitter end: the ubiquitin–proteasome system and cardiac dysfunction. Circulation 115:1456–1463CrossRefPubMed Patterson C, Ike C, PWt Willis, Stouffer GA, Willis MS (2007) The bitter end: the ubiquitin–proteasome system and cardiac dysfunction. Circulation 115:1456–1463CrossRefPubMed
26.
Zurück zum Zitat Sack MN, Smith RM, Opie LH (2000) Tumor necrosis factor in myocardial hypertrophy and ischaemia: an anti-apoptotic perspective. Cardiovasc Res 45:688–695CrossRefPubMed Sack MN, Smith RM, Opie LH (2000) Tumor necrosis factor in myocardial hypertrophy and ischaemia: an anti-apoptotic perspective. Cardiovasc Res 45:688–695CrossRefPubMed
27.
Zurück zum Zitat Sack M (2002) Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 94:23–35CrossRef Sack M (2002) Tumor necrosis factor-alpha in cardiovascular biology and the potential role for anti-tumor necrosis factor-alpha therapy in heart disease. Pharmacol Ther 94:23–35CrossRef
28.
Zurück zum Zitat Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K (2006) C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 7:748–754CrossRef Satoh M, Nakamura M, Akatsu T, Shimoda Y, Segawa I, Hiramori K (2006) C-reactive protein co-expresses with tumor necrosis factor-alpha in the myocardium in human dilated cardiomyopathy. Eur J Heart Fail 7:748–754CrossRef
29.
Zurück zum Zitat Schulz R, Heusch G (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 119:1355–1357CrossRefPubMed Schulz R, Heusch G (2009) Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 119:1355–1357CrossRefPubMed
30.
Zurück zum Zitat Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, Lee RT, Rosenthal N (2005) Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 97:418–426CrossRefPubMed Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, Lee RT, Rosenthal N (2005) Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 97:418–426CrossRefPubMed
31.
Zurück zum Zitat Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K (2005) The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280:20814–20823CrossRefPubMed Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, Sato K, Zeng L, Schiekofer S, Pimentel D, Lecker S, Taegtmeyer H, Goldberg AL, Walsh K (2005) The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 280:20814–20823CrossRefPubMed
32.
Zurück zum Zitat Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, Heusch G (2007) Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 100:140–146CrossRefPubMed Skyschally A, Gres P, Hoffmann S, Haude M, Erbel R, Schulz R, Heusch G (2007) Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. Circ Res 100:140–146CrossRefPubMed
33.
Zurück zum Zitat Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, Geelen P, Verstreken S, Wellens F, Bartunek J (2008) Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 51:129–136CrossRefPubMed Vanderheyden M, Mullens W, Delrue L, Goethals M, de Bruyne B, Wijns W, Geelen P, Verstreken S, Wellens F, Bartunek J (2008) Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol 51:129–136CrossRefPubMed
34.
Zurück zum Zitat Wallace CK, Stetson SJ, Kucuker SA, Becker KA, Farmer JA, McRee SC, Koerner MM, Noon GP, Torre-Amione G (2005) Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant 24:46–51CrossRefPubMed Wallace CK, Stetson SJ, Kucuker SA, Becker KA, Farmer JA, McRee SC, Koerner MM, Noon GP, Torre-Amione G (2005) Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant 24:46–51CrossRefPubMed
35.
36.
Zurück zum Zitat Willis MS, Rojas M, Li L, Selzman CH, Tang RH, Stansfield WE, Rodriguez JE, Glass D, Patterson C (2009) Muscle ring finger-1 (MuRF1) mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol 296:H997–H1006CrossRefPubMed Willis MS, Rojas M, Li L, Selzman CH, Tang RH, Stansfield WE, Rodriguez JE, Glass D, Patterson C (2009) Muscle ring finger-1 (MuRF1) mediates cardiac atrophy in vivo. Am J Physiol Heart Circ Physiol 296:H997–H1006CrossRefPubMed
Metadaten
Titel
Depressed expression of MuRF1 and MAFbx in areas remote of recent myocardial infarction: a mechanism contributing to myocardial remodeling?
verfasst von
Viviane M. Conraads
Christiaan J. Vrints
Inez E. Rodrigus
Vicky Y. Hoymans
Emeline M. Van Craenenbroeck
Johan Bosmans
Marc J. Claeys
Paul Van Herck
Axel Linke
Gerhard Schuler
Volker Adams
Publikationsdatum
01.03.2010
Verlag
D. Steinkopff-Verlag
Erschienen in
Basic Research in Cardiology / Ausgabe 2/2010
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI
https://doi.org/10.1007/s00395-009-0068-5

Weitere Artikel der Ausgabe 2/2010

Basic Research in Cardiology 2/2010 Zur Ausgabe

Ist Fasten vor Koronarinterventionen wirklich nötig?

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

PET kann infarktgefährdete Koronararterien entdecken

04.06.2024 Koronare Herzerkrankung Nachrichten

Der Nachweis aktiver Plaques mittels 18F-Natriumfluorid-PET hilft nicht nur, infarktgefährdete Patienten, sondern auch infarktgefährdete Koronararterien zu erkennen. Von einer gezielten Behandlung vulnerabler Plaques ist man trotzdem weit entfernt.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.